Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389327 | 0.91 | CA1 (0.39) | CA1CA2APPTSHRLMNA | |
| SCHEMBL1389439 | 0.90 | CA1 (0.43) | CA1CA2APPTSHRALDH1A1 | |
| SCHEMBL1389573 | 0.90 | CA1 (0.43) | CA1CA2APPTSHRALDH1A1 | |
| SCHEMBL5022227 | 0.86 | CA1 (0.46) | CA1CA2TSHRALDH1A1LMNA | |
| SCHEMBL22482174 | 0.84 | CA1 (0.50) | CA1CA2TSHRALDH1A1LMNA | |
| SCHEMBL22482247 | 0.81 | CA1 (0.40) | CA1CA2TSHRALDH1A1LMNA | |
| SCHEMBL22123202 | 0.81 | KDM4E (0.41) | APPTSHRALDH1A1GMNNLMNA | |
| SCHEMBL31061327 | 0.81 | L3MBTL1 (0.41) | APPTSHRALDH1A1GMNNLMNA | |
| SCHEMBL4274142 | 0.81 | LMNA (0.49) | APPTSHRALDH1A1GMNNLMNA | |
| SCHEMBL16235813 | 0.77 | EPHX2 (0.38) | CA1CA2TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210047281-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC. (CN) | 2021-02-18 | — | — | US | disclosed |
| WO-2019149255-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都海创药业有限公司 | 2019-08-08 | — | — | WO | disclosed |
| US-7157457-B2 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1324991-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| EP-1586567-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1324991-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026723-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | IDO1, IDO2, TPH1 | CA1 2105/4885CA2 2699/4885APP 689/4885 |
| US-20210047281-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | IDO1, IDO2, TPH1 | CA1 2105/4885CA2 2699/4885APP 689/4885 |
| US-20040058907-A1 | Compounds useful in the treatment of inflammatory diseases | TNF, IL1B, IL4 | CA1 4593/4885CA2 4182/4885APP 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.